Article Types
Letters
Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life‐threatening pathogen within Australian communities
Katherine GC Ong · John R Dyer · Dickon Hayne
Defining the gap, emphasising the deficit
Bridie Mulholland
The New South Wales Pharmacy Trial for herpes zoster: on the nose?
Christian P Pappas · Timothy R Holmes · Minas T Coroneo
Towards national paediatric clinical practice guidelines
Kelvin Hill · Steven McGloughlin · Sharon McGowan · Tari Turner
Genetic testing in cardiovascular disease
Andrew C Martin · Ari E Horton · Shubha Srinivasan
Genetic testing in cardiovascular disease
Michael P Gray · Gemma A Figtree
Planetary care is good cancer care
Nikki Burdett · Ben Dunne
Hepatocellular carcinoma surveillance in Australia: current and future perspectives
Naomi CA Whyler · Sushena Krishnaswamy · Michelle L Giles
“Social prescribing” another stolen Indigenous concept?
Uday N Yadav · Rosemary Wyber · Fiona Cornforth (Wuthathi/Maluilgal) · Raymond W Lovett (Wongaibon/Ngiyampaa)
The rise of direct‐to‐consumer telemedicine services in Australia: implications for primary care and future research
Vishnu Khanal · Deborah J Russell · John Wakerman
Hidden danger: maize starch excipient allergy
Wala Hamid Haj Ali · Corey Borg · Catherine Leggett
The Alfred Health post‐COVID‐19 service, Melbourne, 2020–2022: an observational cohort study
To the Editor: Holland and colleagues reported on the Alfred Health post‐COVID‐19 service experience with the health of patients who had previously been hospitalised, or managed in a hospital‐in‐the‐home setting, with COVID‐19.1 Participants responded to an invitation to register for follow‐up, and then completed a questionnaire. The study also included a separate group (13% of the cohort) who were not necessarily admitted to Alfred Health but lived in the Alfred Health catchment — and might have been managed as outpatients or inpatients in another service but were referred by their local doctors to a specialist clinic targeted for patients with symptoms after initial COVID‐19, and subsequently completed the questionnaire. Sixty per cent of respondents had at least one persistent symptom at eight weeks. The study reported apparently high prevalences of other symptoms, such as post‐traumatic stress disorder in 23%. These results are derived from their cohort and may not be generally applicable. The authors caution: “We could not distinguish between new symptoms and those attributable to other health conditions. Our study did not include a contemporary control group”.1 More importantly, there was no control group of patients hospitalised from non‐COVID‐19 viral illness (with sufficient severe illness to lead to almost 5% spending time in an intensive care unit), who were then concentrated by an invitation, and then sufficiently motivated to fill out a questionnaire. Plausibly in such a group, at eight weeks, 60% would report at least one persistent symptom. Interpretation of their results is also obscured by the patients referred from the community, who came from a bigger population of patients with COVID‐19 concentrated to include only those who sought or agreed to a referral to a specialist follow‐up clinic. The authors wisely identified weaknesses and they should be applauded for their review of their experience. More definitive conclusions about higher rates of persisting ill health caused by COVID‐19 (in comparison to similarly severe infectious illness) might be achieved if they can follow this up — as they perhaps recognise — with a prospective analytic design in a cohort of patients presenting with similar severity of viral illness comparing those with and without COVID‐19 over the long term.
Jeremy L Millar
The Alfred Health post‐COVID‐19 service, Melbourne, 2020–2022: an observational cohort study
In reply: We thank Millar1 for taking the time to respond to our article,2 which details an evaluation of the Alfred Health post‐COVID‐19 clinical service established in June 2020. At that time we, like many health services around the world, faced the challenge of providing ongoing clinical management for patients with persistent and debilitating symptoms following SARS‐CoV‐2 infection, with little evidence to guide service provision or model of care. As there were no data to guide patient selection, we invited all patients with a diagnosis of COVID‐19 who had been managed by our health service (in hospital or in the community) to opt in if they perceived a need for ongoing care. This allowed us to quantify demand, as identified by patients who were affected. Our data confirm that a small proportion (6%) of individuals had persistent symptoms of long COVID that required medical and allied health specialist management. We consider this opt in approach a strength of our report; estimates of ongoing care needs following COVID‐19 vary enormously,3 and our data suggest that demand may be at the lower end of those estimates. As the pandemic progressed and more people with COVID‐19 were managed in the community, we adapted to the clinical needs of our patients by accepting referrals from general practice. We agree that there are limitations to our report, which are inherent in its nature as a service evaluation. We did not aim to provide epidemiological data on the prevalence or characteristics of long COVID; rather, we aimed to document the proportion of our patients following COVID‐19 who identified ongoing care needs, and to describe their characteristics. The recent federal parliamentary inquiry into long COVID4 states that “The role of specific long COVID clinics as a resource for primary health providers is very important to allow adequate services for major complications” and calls for the establishment of multidisciplinary long COVID clinics in selected public hospitals. We hope that our experience might be informative for other health services who are seeking to provide care for this small but important group of patients.
Anne Holland · Simone Dal Corso
Skin fragility disorder misdiagnosed as child abuse: a cautionary tale
Heather G Mack · Fred K Chen · John R Grigg
Health care service use by people diagnosed with invasive melanoma in Queensland: a benefit incidence analysis
Ross S Bailie · Megan Passey · Edward Jegasothy
Health care service use by people diagnosed with invasive melanoma in Queensland: a benefit incidence analysis
Daniel Lindsay · David C Whiteman · Louisa G Collins
Enhanced recovery after surgery: an update for the generalist
Barbara Depczynski · Brenda Ta · Sue Mei Lau
Is the current commercial model of medicinal cannabis in the best interest of patients?
Richard CJ Bradlow · Ferghal Armstrong